MWNA
FULC icon

Marshall Wace North America’s Fulcrum Therapeutics FULC Stock Holding History

Marshall Wace North America’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$2.68M Buy
+95,104
New +$1.8M 0.01% 663

Other funds holding FULC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Marshall Wace North America's FULC Position: Q3 2021 in Review

Marshall Wace North America opened a new position in Fulcrum Therapeutics (FULC) in Q3 2021: 95,104 shares worth $2.68M. The stake represents 0.01% of the portfolio and ranks #663 among its holdings.

101 funds tracked by Wall St. Rank hold FULC as of Q3 2021.

  • Marshall Wace North America held 95,104 shares of Fulcrum Therapeutics worth $2.68M as of Q3 2021.
  • Fulcrum Therapeutics was a new Marshall Wace North America position in Q3 2021.
  • Fulcrum Therapeutics made up 0.01% of Marshall Wace North America's portfolio in Q3 2021, its #663 holding.
  • 101 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.